Postpartum bleeding

More hysterectomies can be averted with earlier uterine artery embolization for postpartum hemorrhage

Retrieved on: 
Saturday, March 23, 2024
Health, Postpartum bleeding, Hysterectomy, Uterus, Internal bleeding, Uterine artery embolization, Incidence, Abdominal pain, Patient, Uncontrolled, Research, Bleeding, University, Society, Artery, Woman, Treatment, Blood, Birth control

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- Early intervention with a minimally invasive treatment called uterine artery embolization (UAE) can help women avoid hysterectomy due to severe bleeding after childbirth, according to a new study being presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • The study was a retrospective review of 66 patients (median age, 31) who underwent UAE for uncontrolled postpartum hemorrhage at a single, high-volume medical center between 2014 and 2022.
  • Postpartum hemorrhage is a rare but potentially deadly complication of childbirth.
  • The study found that it was more likely to occur in patients who experienced greater blood loss before embolization.
  • Abstract #189 : Short-Term and Long-Term Outcomes of Uterine Artery Embolization for Treatment of Uncontrolled Post-Partum Hemorrhage.

The Worldwide Postpartum Hemorrhage Devices Industry is Expected to Reach $1 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Medical Devices, Health, Consumer, Surgery, Women, Baby, Maternity, Smart contract, Bleeding, Lists of countries and territories, Maternal death, Postpartum bleeding, Internal bleeding, Gynaecology, PPH, Death, Childbirth, Oxytocin, Disease, Obstetrics, Mortality, Uterus, World, UBT, Hypovolemia, CAGR, Hysterectomy, World Health Organization, Tranexamic acid, Don't Underestimate My Love for You, American College, Uterine balloon tamponade, Method, WHO, Pet, Birth control

The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.

Key Points: 
  • The Global Postpartum Hemorrhage (PPH) Devices Market size is expected to reach $1.05 billion by 2028, rising at a market growth of 5.2% CAGR during the forecast period.
  • Postpartum hemorrhage (PPH) is the most prevalent type of obstetric hemorrhage and one of the primary causes of maternal mortality.
  • The postpartum hemorrhage devices market is growing due to a rise in complications such as acute postpartum hemorrhage.
  • Underestimations of blood loss lead healthcare providers into believing that deployment of postpartum hemorrhage are not necessary, thus, limiting the use of postpartum hemorrhage devices.

Postpartum hemorrhage cart and medication kit interventions improve response to leading cause of maternal morbidity

Retrieved on: 
Tuesday, January 25, 2022
Joint Commission, Internal bleeding, Disease, Maintenance, Collection, Bleeding, Health, Woman, Pregnancy, Quality, Time, Lean Six Sigma, Postpartum bleeding, L&D, Mortality, MPH, PPH, Map, Editorial, GLOBE, Safety, Pharmaceutical industry, Medicine, MD

OAKBROOK TERRACE, Illinois, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity in the United States.

Key Points: 
  • OAKBROOK TERRACE, Illinois, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity in the United States.
  • The researchers created a simulation dictating the collection of a prespecified list of supplies commonly used in response to PPH.
  • The simulation was repeated after developing, creating and deploying two interventions:
    Intervention 1: A cart containing the supplies most used in response to PPH.
  • Rapid access to the contents of the kit should go a long way toward decreasing maternal morbidity and mortality from hemorrhage.

 Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Women's health, Human reproduction, Medical specialties, Motherhood, Transfusion medicine, Midwifery, Childbirth, Carbetocin, Peptides, Postpartum bleeding, Bleeding, Caesarean section

Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.

Key Points: 
  • Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.
  • Until now, the first-choice drug for preventing excessive bleeding after birth required storage and transportation at 28C, typically in a refrigerator to maintain its effectiveness.
  • Carbetocin Ferring is a heat-stable formulation with predictable quality offering an additional option for healthcare professionals in preventing excessive bleeding after childbirth.
  • Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries.

Organon Completes Acquisition of Alydia Health – A Medical Device Company Focused on Postpartum Hemorrhage

Retrieved on: 
Wednesday, June 16, 2021
Health, Medical devices, Consumer, Hospitals, Women, Baby, Maternity, General Health, Midwifery, Human reproduction, Motherhood, Women, Women's health, Transfusion medicine, Childbirth, Obstetrics, Postpartum bleeding, Postpartum period, Maternal health, Bleeding

Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Alydia Health, a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Alydia Health, a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
  • On June 3, 2021, Organon launched as a new company committed to womens everyday health needs, with a focus on reproductive health, health issues that affect women as well as conditions that disproportionately affect women.
  • Alydia Health is thrilled to be joining a company that can help progress our founding vision through its commitment to listen to women, to understand her health needs and to bring forward more options, said Rob Binney, Chief Executive Officer, Alydia Health.
  • Founded in 2010 with a vision to make childbirth safer for all mothers, Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding a challenging condition to manage and a growing problem in the U.S. and globally.

Hysterectomy used more for postpartum bleeding compared to less invasive option

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Medicine, Clinical medicine, Midwifery, Postpartum bleeding, Postpartum period, Hysterectomy, Medicaid, Childbirth, Healthcare Cost and Utilization Project

"All patients should have consistent access to a treatment that is safer, has an easier recovery and could preserve their ability to continue to have children."

Key Points: 
  • "All patients should have consistent access to a treatment that is safer, has an easier recovery and could preserve their ability to continue to have children."
  • Hysterectomy was twice as common as embolization in Hispanic patients, and also more common in rural and nonteaching urban hospitals, in the South and among Medicaid and self-paying patients.
  • "Postpartum hemorrhage can occur quickly, and effective treatment options should be readily available to every woman having a child in the United States," said Newsome.
  • Researchers used the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database, which tracks every hospital admission in the United States, and examined the results of significant postpartum bleeding, which occurred in 3.1 percent of live births.

Alydia Announces $13.9 Million Financing for Innovative Postpartum Hemorrhage Treatment, Appoints Robert Binney as CEO and Colby Holtshouse as COO

Retrieved on: 
Thursday, July 30, 2020
Medical devices, Women, Consumer, Health, Baby, Maternity, Midwifery, RTT, Women, Parenting, Childbirth, Women's health, Motherhood, Postpartum period, Postpartum bleeding, AXA, Binney, Alydia Health, AXA Investment Managers

In association with the financing, Dr. Zina Affas Besse, Managing Partner at Global Health Funds will join the companys board of directors.

Key Points: 
  • In association with the financing, Dr. Zina Affas Besse, Managing Partner at Global Health Funds will join the companys board of directors.
  • Alydia Healths device for postpartum hemorrhage has tremendous potential to improve outcomes for mothers and families around the world, said Jonathan Dean, Head of Impact Investing at AXA Investment Managers.
  • We are proud to invest in some of the most innovative technologies that address major public health issues worldwide, while generating attractive social and financial returns.
  • Rob Binney Joins as CEO, Colby Holtshouse Appointed COO
    The company also announced the appointment of seasoned medical device executive Robert Binney as Chief Executive Officer.

Swissmedic Approves Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births

Retrieved on: 
Wednesday, May 13, 2020
Science, Women, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical trials, RTT, Obstetrics, Drugs, Branches of biology, Peptides, Women's health, Midwifery, Carbetocin, Postpartum bleeding, Ferring Pharmaceuticals, Uterotonic, Oxytocin

Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section.5

Key Points: 
  • Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section.5
    This press release features multimedia.
  • Ferring will supply Carbetocin Ferring from state-of-the-art manufacturing sites that have passed Good Practice Manufacturing inspections by stringent regulatory authorities.7
    The loss of any woman during childbirth is a tragedy.
  • Heat-stable carbetocin is included on the World Health Organization (WHO) Model List of Essential Medicines (EML),8 and in the WHO recommendations on uterotonics for the prevention of postpartum haemorrhage.
  • **6
    CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH,*** was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth.

Alydia Health Completes Enrollment of its Pivotal PEARLE IDE Study in Women with Postpartum Hemorrhage

Retrieved on: 
Wednesday, February 5, 2020
Health, Medical devices, Consumer, Hospitals, Women, Parenting, Clinical trials, RTT, Motherhood, Human reproduction, Midwifery, Women, Childbirth, Women's health, Postpartum bleeding, Transfusion medicine, Postpartum period, Vaginal bleeding, Bakri balloon, Postpartum Hemorrhage and Abnormal Postpartum Uterine Bleeding, Alydia Health

Alydia Health, a clinical-stage medical device company dedicated to making childbirth safer for all mothers, today announced that the company has completed enrollment in the pivotal PEARLE IDE Study.

Key Points: 
  • Alydia Health, a clinical-stage medical device company dedicated to making childbirth safer for all mothers, today announced that the company has completed enrollment in the pivotal PEARLE IDE Study.
  • The PEARLE Study is investigating the safety and effectiveness of the Jada System, an innovative technology designed to rapidly control and treat abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH).
  • In this study, over 100 women enrolled and were treated with Jada after experiencing abnormal bleeding or PPH.
  • About Postpartum Hemorrhage and Abnormal Postpartum Uterine Bleeding:
    Immediately following childbirth, the uterus should contract to stop the normal bleeding associated with delivery.

Alydia Health Announces the Addition of Erica Rogers to its Board of Directors

Retrieved on: 
Friday, January 10, 2020
General Health, Medical devices, Hospitals, Health, Clinical trials, Midwifery, Articles, Motherhood, Women's health, RTT, Human reproduction, Childbirth, Postpartum period, Maternal health, Postpartum bleeding, Health, Postpartum Hemorrhage and Abnormal Postpartum Uterine Bleeding, Alydia Health

Ms. Rogers has successfully driven nearly every aspect of a companys growth, from founding to commercializing some of todays most innovative products on the market.

Key Points: 
  • Ms. Rogers has successfully driven nearly every aspect of a companys growth, from founding to commercializing some of todays most innovative products on the market.
  • Her broad expertise will help Alydia meet our goal of truly changing the standard of care for maternal health in the U.S. and around the world.
  • Alydia Health is addressing this major problem in womens health by focusing on postpartum hemorrhage treatment, said Erica Rodgers.
  • For more information, visit www.alydiahealth.com or follow @AlydiaHealth on Twitter, @Alydia Health on LinkedIn.